Publications by authors named "Y Arkam"
Article Synopsis
- - The phase II trial assessed the effectiveness of the RiBVD treatment (rituximab, bendamustine, velcade, and dexamethasone) in patients over 65 with mantle cell lymphoma (MCL), which resulted in a median progression-free survival of 79 months and overall survival of 111 months.
- - TP53 mutation status and albumin levels were identified as significant prognostic factors, with TP53 mutations linked to a higher risk of shorter progression-free survival and overall survival in the analyzed patient population.
- - A scoring system combining TP53 mutation status and albumin levels allowed differentiation of patient outcomes, indicating varying survival rates based on the presence of these factors, thus enhancing prognostic assessments
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Francois Guilhot Françoise Rigal-Huguet Joëlle Guilhot Agnès-Paule Guerci-Bresler Frédéric Maloisel Yazid Arkam
Leukemia
August 2021
Article Synopsis
- - The SPIRIT trial is a long-term study that compares the effectiveness of various treatments for chronic-phase chronic myeloid leukaemia (CML), involving 787 patients followed for an average of 13.5 years.
- - Overall and progression-free survival rates after 15 years were similar across four treatment groups, ranging from 80% to 87%, suggesting comparable effectiveness of different combinations.
- - The combination of imatinib with pegylated interferon alpha2a resulted in significantly better molecular response rates compared to imatinib alone, although toxicity led to treatment cessation for some patients.
Article Synopsis
- Two FDA-approved CAR T cell therapies, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), were studied in a retrospective analysis of 70 patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) to evaluate their usage, effectiveness, and safety.
- The study found overall response rates (ORRs) of 63% at 1 month and 45% at 3 months, with median progression-free survival (PFS) of 3.0 months and overall survival (OS) of 11.8 months, indicating significant but variable effectiveness across patients.
- Common side effects included cytokine release syndrome (CR